FineMark National Bank & Trust acquired a new position in shares of NuVasive, Inc. (NASDAQ:NUVA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,500 shares of the medical device company’s stock, valued at approximately $248,000.
Several other large investors also recently bought and sold shares of NUVA. Guggenheim Capital LLC increased its holdings in shares of NuVasive by 12.0% during the 1st quarter. Guggenheim Capital LLC now owns 12,026 shares of the medical device company’s stock worth $627,000 after purchasing an additional 1,285 shares during the period. Legal & General Group Plc increased its holdings in shares of NuVasive by 11.3% during the 1st quarter. Legal & General Group Plc now owns 51,828 shares of the medical device company’s stock worth $2,706,000 after purchasing an additional 5,258 shares during the period. Xact Kapitalforvaltning AB increased its holdings in shares of NuVasive by 33.9% during the 1st quarter. Xact Kapitalforvaltning AB now owns 6,716 shares of the medical device company’s stock worth $351,000 after purchasing an additional 1,700 shares during the period. Principal Financial Group Inc. increased its holdings in shares of NuVasive by 4.3% during the 1st quarter. Principal Financial Group Inc. now owns 226,509 shares of the medical device company’s stock worth $11,826,000 after purchasing an additional 9,438 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of NuVasive during the 2nd quarter worth about $304,000.
Shares of NuVasive stock opened at $59.02 on Friday. The company has a current ratio of 3.45, a quick ratio of 1.83 and a debt-to-equity ratio of 0.74. NuVasive, Inc. has a twelve month low of $44.62 and a twelve month high of $72.41. The stock has a market cap of $2.90 billion, a PE ratio of 30.90, a price-to-earnings-growth ratio of 1.69 and a beta of 0.78.
Several research analysts have recently issued reports on NUVA shares. Robert W. Baird upgraded shares of NuVasive from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $60.00 to $82.00 in a report on Thursday, September 27th. Morgan Stanley boosted their price objective on shares of NuVasive from $55.00 to $77.00 and gave the stock a “hold” rating in a report on Tuesday, September 25th. TheStreet upgraded shares of NuVasive from a “c+” rating to a “b-” rating in a report on Thursday, August 2nd. Canaccord Genuity boosted their price objective on shares of NuVasive from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, September 18th. Finally, BidaskClub downgraded shares of NuVasive from a “strong-buy” rating to a “buy” rating in a report on Friday, September 21st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $67.63.
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Story: What is the 52-week high/low?
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.